<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742140</url>
  </required_header>
  <id_info>
    <org_study_id>Mg SO4 injections</org_study_id>
    <nct_id>NCT04742140</nct_id>
  </id_info>
  <brief_title>Magnesium Sulphate Injection in Treatment of Myofascial Trigger Points</brief_title>
  <official_title>Magnesium Sulphate Injection in Treatment of Myofascial Trigger Points in Masseter Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fayoum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fayoum University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single- center, randomized (1:1) clinical trial comparing the&#xD;
      effectiveness of magnesium sulphate injections in treatment of myofascial trigger points in&#xD;
      the masseter muscle versus the saline injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposal presents the magnesium sulphate (MgSO4) as a possible injection treatment for&#xD;
      TrPs. The MgSO4 prevents the release of pre-synaptic acetylcholine from neuromuscular and&#xD;
      sympathetic junctions that could explain the ability of the MgSO4 to relax the muscle and&#xD;
      reduce pain Specific aim: evaluate the effectiveness of magnesium sulphate injections in&#xD;
      treatment of myofascial trigger points in the masseter muscle versus the saline injection.&#xD;
&#xD;
      Hypothesis: the injection of masseter muscle trigger points with magnesium sulphate is more&#xD;
      effective than saline injection in pain relief.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain score</measure>
    <time_frame>6 months postoperative</time_frame>
    <description>pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality-of-life in an Oral Health Impact Profile questionnaire (OHIP-14)</measure>
    <time_frame>six months postoperative</time_frame>
    <description>OHIP-14 is used to measure patients' self-reported discomfort, disability, and functional limitation due to oral conditions with scores ranging from 0 to 56 (with 56 representing a subject answering ''very often'' to all 14 items)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Trigger Point Pain, Myofascial</condition>
  <arm_group>
    <arm_group_label>group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>each patient injected 0.5ml in each TrPs of saline by the same operator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each patient injected 0.5ml in each TrPs of magnesium sulphate by the same operator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>each patient injected 0.5ml in each TrPs of magnesium sulphate according to the treatment group by the same operator</description>
    <arm_group_label>group II</arm_group_label>
    <other_name>Study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>each patient injected 0.5ml in each TrPs of saline according to the treatment group by the same operator</description>
    <arm_group_label>group I</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Definite diagnosis of myofascial pain with a referral, based on the DC/TMD criteria&#xD;
&#xD;
          -  the presence of one or more trigger points in the unilateral or bilateral masseter&#xD;
             muscle&#xD;
&#xD;
          -  no history of any invasive procedures in the related masseter muscle.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Factors that can cause pain in the orofacial region other than MTPs (decayed tooth,&#xD;
             TMJ internal disorder).&#xD;
&#xD;
          -  Any systemic disease that possibly affects the masticatory system such as rheumatoid&#xD;
             arthritis and epilepsy&#xD;
&#xD;
          -  pregnancy and lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alshaimaa Mohamed, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fayoum University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alshaimaa Mohamed, PhD</last_name>
    <phone>+201006047940</phone>
    <email>aas16@fayoum.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Dentistry</name>
      <address>
        <city>Fayoum</city>
        <zip>63514</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alshaimaa A Shabaan, PhD</last_name>
      <phone>+201006047940</phone>
      <email>aas16@fayoum.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Aliaa I Mahroun, PhD</last_name>
      <phone>+01005714585</phone>
      <email>aim11@fayoum.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Yilmaz O, Sivrikaya EC, Taskesen F, Pirpir C, Ciftci S. Comparison of the Efficacy of Botulinum Toxin, Local Anesthesia, and Platelet-Rich Plasma Injections in Patients With Myofascial Trigger Points in the Masseter Muscle. J Oral Maxillofac Surg. 2021 Jan;79(1):88.e1-88.e9. doi: 10.1016/j.joms.2020.09.013. Epub 2020 Sep 14.</citation>
    <PMID>33045182</PMID>
  </reference>
  <reference>
    <citation>Yousef AA, Al-deeb AE. A double-blinded randomised controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component. Anaesthesia. 2013 Mar;68(3):260-6. doi: 10.1111/anae.12107. Epub 2012 Dec 17.</citation>
    <PMID>23384256</PMID>
  </reference>
  <reference>
    <citation>Sakalys D, Rokicki JP, Januzis G, Kubilius R. Plasma rich in growth factors injection effectiveness for myofascial pain treatment in masticatory muscles. Randomised controlled trial. J Oral Rehabil. 2020 Jul;47(7):796-801. doi: 10.1111/joor.12973. Epub 2020 Apr 21.</citation>
    <PMID>32271467</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 30, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fayoum University</investigator_affiliation>
    <investigator_full_name>Alshaimaa Ahmed shabaan</investigator_full_name>
    <investigator_title>associate professor in oral &amp; maxillofacial Surgery Department</investigator_title>
  </responsible_party>
  <keyword>trigger point</keyword>
  <keyword>masseter muscle</keyword>
  <keyword>myofascial pain</keyword>
  <keyword>magnesium sulphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

